GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET FORECAST 2018-2026

GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET FORECAST 2018-2026

  • August 2018 •
  • 145 pages •
  • Report ID: 5486788 •
  • Format: PDF
KEY FINDINGS
The global cell-free DNA (cfDNA) testing market is anticipated to register a CAGR of 18.52% between the forecasted years of 2018-2026. Factors such as the global increase in the number of people suffering from chronic diseases, advances in molecular pathogenesis and a surge in prenatal complication are increasing the market demand for cell-free DNA testing.

MARKET INSIGHTS
The Global Cell-free DNA (cfDNA) testing market is segmented on the basis of products, platforms and applications.The product segment of this market includes automated instruments, consumables and extraction/isolation kits.

The extraction isolation kits can be either magnetic bead-based, column-based or other extraction/isolation kits.The various platforms for the cell-free DNA testing market are NGS, rPCR and multiplexed PCR, qPCR, dPCR and other platform.

The market chiefly finds its application in areas like oncology, NIPT and other disease conditions.

REGIONAL INSIGHTS
Regional segmentation of the global cell-free DNA market is done into Asia-Pacific, Europe, North America, and rest of the world.The North American market is likely to account for the highest revenue share by the end of the forecast period of 2018-2026.

The growing prevalence of cancer is increasing the demand for cell-free DNA tests. These tests are also being employed in prenatal screening.

COMPETITIVE INSIGHTS
The leading companies operating in this market are Agilent Technologies Inc, Accubiomed, Aline Biosciences, Berry Genomics, Bioo Scientific Corporation, F. Hoffmann-La Roche Ltd, Gatc Biotech Ag. (Acquired By Eurofins Scientific), Illumina, Laboratory Corporation Of America, Merck Kgaa, Natera Inc, Nipd Genetics, Premaitha Health Plc, Qiagen N.V, and Thermo Fisher Scientific Inc.